CIAM
NRIX icon

Caitong International Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Caitong International Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,820
Closed -$53.5K – 2903
2025
Q4 		$53.5K Buy
+2,820
New +$40.5K 0.01% 675
2025
Q3 		– Sell
-519
Closed -$5.91K – 2334
2025
Q2 		$5.91K Buy
519
+482
+1,303% +$5.21K ﹤0.01% 949
2025
Q1 		$440 Buy
37
+24
+185% +$401 ﹤0.01% 1805
2024
Q4 		$245 Buy
+13
New +$298 ﹤0.01% 1565

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Caitong International Asset Management's NRIX Position: Q1 2026 in Review

Caitong International Asset Management sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 2,820 shares — an estimated $53.5K sold.

Caitong International Asset Management first reported a position in NRIX in Q4 2024 and held it in 4 quarters. The position peaked at $53.5K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Caitong International Asset Management reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caitong International Asset Management sold 2,820 Nurix Therapeutics shares in Q1 2026, an estimated $53.5K.
  • Caitong International Asset Management first reported a position in Nurix Therapeutics in Q4 2024 and held it in 4 quarters.
  • Caitong International Asset Management's Nurix Therapeutics position peaked at $53.5K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.